News & events

Press Releases

On the 28th March 2022, OncoArendi changed its name to Molecure

Molecure has confirmed the in vitro activity of another molecule binding to a new mRNA target within the mRNA discovery platform

12 June 2024

Molecure receives approval to initiate a Phase II clinical trial (KITE) for OATD-01 for the treatment of pulmonary sarcoidosis in selected countries of the European Union and Norway

21 May 2024

Molecure has published its financial report for the first quarter of 2024. The company is progressing, as anticipated, the next steps in the development of its clinical and pre-clinical programmes

17 May 2024

Molecure has published its financial report for 2023 – the company has significantly accelerated the development of its clinical and pre-clinical programmes and plans to make strong progress in research in 2024 and 2025

29 March 2024

Invitation to investor meeting 10th April 2024, 2:00 pm (CET)

28 March 2024

First patient in the UK is dosed in the OATD-01 Phase 2 KITE study in pulmonary sarcoidosis

22 March 2024

Events & Presentations

R&D Day Presentation, 07.12.2022

7 December 2022

Fibrosis and Tissue Repair: From Molecules and Mechanics to Therapeutic Approaches – February 19-23, 2020 | Victoria, BC, Canada

27 February 2020

EFMC-ASMC’19 – September 1-5, 2019 | Athens, Greece

11 September 2019

ACS National Meeting & Expo – August 25 – 29, 2019 | San Diego, CA

4 September 2019

ATS- International Conference – Dallas, 17-22.05.2019

22 May 2019

EFMC – YMCS – Young Medicinal Chemist Symposium – Ljubljana 02-06.09.2018

17 September 2018